Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2018
Pharma News, 2018
FDA approves first new flu drug in nearly 20 years
(CNN) -- Flu sufferers now have a new option for relieving symptoms.
New study bolsters hypothesis that herpes virus causes Alzheimer's
A new review article published in the journal Frontiers in Aging Neuroscience has summarized the most recent evidence supporting the controversial hypothesis that Herpes Simplex Virus 1 (HSV1...
Scientists reveal new details of how a naturally occurring hormone can boost memory in aging mice
A Columbia study in mice has revealed new details of how a naturally occurring bone hormone reverses memory loss in the aging brain.
Amgen cuts price of cholesterol drug Repatha by 60 percent
(Reuters) - Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication’s U.
Pfizer-Lilly non-opioid drug helps reduce osteoarthritis pain
(Reuters) - A non-opioid drug developed by Pfizer and Eli Lilly met the main goals of a late-stage study, in which over half of the patients reported a significant reduction in osteoarthritis ...
Consumer deal fever hits Johnson & Johnson with $2.1B deal to buy out Japan's Ci:z
Add another Big Pharma company to the wheeling and dealing in consumer health.
AbbVie rheumatoid arthritis drug succeeds in late stage trial
NEW YORK (Reuters) - AbbVie Inc on Tuesday said its experimental rheumatoid arthritis (RA) treatment showed significant improvement in physical function, pain and quality of life compa...
AstraZeneca digs deeper into cancer with Innate stake
LONDON/PARIS (Reuters) - AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.
Takeda buys stake in Enterome’s microbiome Crohn’s drug
Takeda has paid $50 million (€44 million) upfront to co-develop Enterome’s early-phase Crohn’s disease candidate EB8018.
U.S. scientists create new drug to sustain oxygen-starved hearts
SAN FRANCISCO, Oct.
Phase II trial of capmatinib demonstrates positive results in NSCLC
Novartis said that the phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) has demonstrated positive results in patients with MET mutated advanced non-small cell lun...
Molecule-level 'CT scans' could lead to faster drug discovery
Scientists like to use x-rays when determining chemical structures to develop drugs, but it's an agonizingly slow process.
10
11
12
13
14
15
16
17
18
